| Description | RS 2135 is a novel class I antiarrhythmic agent to inhibit ischemia-induced ventricular arrhythmias. |
| Synonyms | RS2135, RS-2135 |
| molecular weight | 332.83 |
| Molecular formula | C18H21ClN2O2 |
| CAS | 133775-36-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Yorikane R, Sada T, Koike H. Electrophysiologic effects of RS-2135, a new antiarrhythmic compound, on canine Purkinje fibers. J Cardiovasc Pharmacol. 1992 Dec;20(6):955-60. PubMed PMID: 1282599. 2. Yorikane R, Mizuno H, Itoh Y, Miyake S, Koike H. Effects of RS-2135, a novel class I antiarrhythmic agent, on sustained ventricular tachycardia after coronary embolization in conscious dogs. J Cardiovasc Pharmacol. 1994 Jul;24(1):28-36. PubMed PMID: 7521486. 3. Yorikane R, Sada T, Koike H. Effects of RS-2135, a new antiarrhythmic agent, on the kinetics of use-dependent decrease in maximum upstroke velocity in guinea pig ventricular myocardium. J Cardiovasc Pharmacol. 1993 Mar;21(3):430-4. PubMed PMID: 7681504. 4. Ito K, Nagafuchi K, Taga A, Yorikane R, Koike H. Possible involvement of altered Na+ -Ca2+ exchange in negative inotropic effects of class I antiarrhythmic drugs on rabbit and rat ventricles. J Cardiovasc Pharmacol. 1996 Mar;27(3):355-61. PubMed PMID: 8907796. |